# A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

> **NCT06840392** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 555 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Remibrutinib Dose A
- **DRUG:** Remibrutinib Dose B
- **DRUG:** Placebo 1
- **DRUG:** Placebo 2

## Key facts

- **NCT ID:** NCT06840392
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2027-10-29
- **Final completion:** 2028-02-07
- **Target enrollment:** 555 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06840392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06840392, "A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06840392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*